Metavia Stock Surges After 1-for-11 Reverse Split Amid Promising Obesity Trial Data

Introduction

METAVIA INC (Nasdaq: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2017, the firm is focused on developing pharmaceuticals for cardiometabolic diseases, with lead programs targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Its two pipeline candidates are DA-1241, a GPR119 agonist intended for MASH and type 2 diabetes, and DA-1726, a dual GLP-1/glucagon receptor agonist designed for once-weekly subcutaneous dosing in obesity.

Corporate Structure

METAVIA INC is listed on the Nasdaq Capital Market as a small-cap company. Key points:

• Employees: 11–50
• Headquarters: Cambridge, Massachusetts
• Strategic partner: Dong-A ST Co. Ltd., providing R&D, scientific, and CMC expertise
• Public float: Approximately 2.2 million shares outstanding after the December 4, 2025, reverse split

Biotechnology by Louis Reed

Recent Developments and News

On December 2, 2025, METAVIA announced a 1-for-11 reverse stock split of its common shares, effective December 4, 2025, to meet Nasdaq’s continued listing requirements. Outstanding shares decreased from about 25.4 million to approximately 2.3 million, with all trading thereafter adjusted on a split-basis under ticker MTVA.

At scientific and investor forums in the autumn of 2025:

• November 4–7: Two abstracts on DA-1726 were accepted for poster presentations at ObesityWeek® 2025 in Atlanta
• November 7–11: An abstract on DA-1241 was accepted for poster presentation at the AASLD Liver Meeting 2025 in Washington, D.C.
• September 16–17: CEO Hyung Heon Kim presented at the Obesity Science & Innovation conference in Boston
• Q3 2025 earnings reported Phase 1 data for DA-1726, showing mean body-weight reductions up to 6.3% in the 32 mg cohort, with results from an extended 48 mg cohort expected by December 31, 2025

Multiple Form 8-K filings in November and December 2025 documented these corporate actions and event participations.

Financial and Strategic Analysis

As of December 8, 2025, MTVA shares closed at $11.7696, reflecting a 43.85% increase on a volume of 199,694 shares. According to CNBC:

• Market capitalization: $18.0 million
• Shares outstanding: 2.20 million
• EPS (TTM): –13.88; P/E (TTM): –0.59; Forward P/E: –1.29
• Beta: 0.27

The reverse stock split resulted in a reduction of share count and a proportional increase in exercise prices of equity awards. Strategically, METAVIA utilizes its partnership with Dong-A ST for manufacturing and development support, while its dual-agonist and GPR119 platforms aim to address significant opportunities in cardiometabolic therapeutics.

Market Position and Industry Context

METAVIA operates within a growing GLP-1 and cardiometabolic market anticipated to expand at a 17.46% CAGR through 2030. Competitors including Eli Lilly and Novo Nordisk have raised interest in peptide-based therapies. METAVIA’s emphasis on novel dual agonists and GPR119 modulation aims to differentiate its pipeline. As a small-cap biotechnology company, the forthcoming clinical readouts and regulatory filings will influence its competitive stance against larger firms.

TL;DR

• December 4, 2025: 1-for-11 reverse stock split reduces outstanding shares to approximately 2.3 million
• December 8, 2025 share price: $11.7696 (+43.85%) on a volume of 199,694
• Q3 2025 Phase 1 obesity data: mean body-weight reductions of up to 6.3% in DA-1726 32 mg cohort; 48 mg results due by December 31, 2025
• November 2025 abstracts accepted at ObesityWeek® and AASLD Liver Meeting
• Upcoming year-end and early 2026 presentations and readouts will inform the company’s clinical and financial outlook